Cargando…

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy

Serous ovarian cancer (SOC) is a significant cause of morbidity and mortality in females with poor prognosis because of advanced stage at presentation. Recently, neoadjuvant chemotherapy (NACT) is being used for management of advanced SOC, but role of tissue biomarkers in prognostication following N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khandakar, Binny, Mathur, Sandeep R., Kumar, Lalit, Kumar, Sunesh, Datta Gupta, Siddhartha, Iyer, Venkateswaran K., Kalaivani, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016870/ https://www.ncbi.nlm.nih.gov/pubmed/24864239 http://dx.doi.org/10.1155/2014/401245

Ejemplares similares

Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
por: Sethi, Ankita, et al.
Publicado: (2022)

Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population
por: Kumari, Sarita, et al.
Publicado: (2021)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Early-Stage epithelial ovarian cancer: Predictors of survival
por: Upadhyay, Avinash, et al.
Publicado: (2022)

Ovarian stromal tumor with minor sex cord elements with coexistent endometrial carcinoma
por: Kumar, Sunesh, et al.
Publicado: (2013)

Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Deen, Surrin S., et al.
Publicado: (2019)

Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel
por: Sehrawat, Urmila, et al.
Publicado: (2016)

Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis
por: Sharma, Aparna, et al.
Publicado: (2019)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2023)

Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer
por: Patel, Ami, et al.
Publicado: (2021)

Predictors of chemotherapy resistance & relapse in gestational trophoblastic neoplasia
por: Singhal, Seema, et al.
Publicado: (2020)

Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma
por: XIE, MENG, et al.
Publicado: (2014)

Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer
por: Győrffy, Balázs
Publicado: (2023)

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
por: Rundo, Leonardo, et al.
Publicado: (2022)

Utility of a limited panel of calretinin and Ber-EP4 immunocytochemistry on cytospin preparation of serous effusions: A cost-effective measure in resource-limited settings
por: Arora, Raman, et al.
Publicado: (2011)

Identification of an Individualized Prognostic Biomarker for Serous Ovarian Cancer: A Qualitative Model
por: Luo, Fengyuan, et al.
Publicado: (2022)

Prognostic value of complete metabolic response on (18)F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2022)

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
por: Chung, Young Shin, et al.
Publicado: (2018)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Cytomorphologic consideration in malignant ascites with renal cell carcinoma: A report of two cases
por: Gupta, Ruchika, et al.
Publicado: (2010)

External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
por: Lee, Jung-Yun, et al.
Publicado: (2017)

The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma
por: Shen, Yuanming, et al.
Publicado: (2022)

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
por: Partheen, Karolina, et al.
Publicado: (2009)

Expression of DKK1 in Endometrial Endometrioid Carcinoma and Its Correlation with Wnt/β-catenin Signalling Pathway
por: Das, Abhijit, et al.
Publicado: (2023)

Primary ovarian non-Hodgkin lymphoma: Diagnosis of two cases on fine needle aspiration cytology
por: Yadav, Rajni, et al.
Publicado: (2016)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN)
por: Bund, Virginie, et al.
Publicado: (2020)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
por: Dhiman, Pravesh, et al.
Publicado: (2022)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
por: Dhiman, Pravesh, et al.
Publicado: (2022)

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer
por: Lecuelle, Julie, et al.
Publicado: (2021)

AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer
por: Hojnik, Marko, et al.
Publicado: (2022)

KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma
por: Sun, Zhe, et al.
Publicado: (2023)

Immune checkpoint inhibitor therapy associated enteritis mimicking celiac disease
por: Khandakar, Binny, et al.
Publicado: (2023)

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
por: McDonald, Megan E., et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
por: Liontos, M., et al.
Publicado: (2021)

p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category
por: Walia, Ritika, et al.
Publicado: (2017)

BDP1 as a biomarker in serous ovarian cancer
por: Cabarcas‐Petroski, Stephanie, et al.
Publicado: (2022)

Resistance prediction in high‐grade serous ovarian carcinoma with neoadjuvant chemotherapy using data‐independent acquisition proteomics and an ovary‐specific spectral library
por: Qian, Liujia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8nnkrvt0hho4c21jbkqf00stqh